Cullen Frost Bankers Inc. Has $1.81 Million Holdings in Baxter International Inc. (NYSE:BAX)

Cullen Frost Bankers Inc. reduced its stake in shares of Baxter International Inc. (NYSE:BAX) by 45.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,208 shares of the medical instruments supplier’s stock after selling 51,066 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Baxter International were worth $1,814,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Riverview Trust Co raised its stake in Baxter International by 5,488.2% during the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 933 shares during the last quarter. LRI Investments LLC raised its stake in Baxter International by 60.8% during the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 590 shares during the last quarter. CKW Financial Group raised its stake in Baxter International by 100.0% during the 3rd quarter. CKW Financial Group now owns 2,200 shares of the medical instruments supplier’s stock valued at $81,000 after purchasing an additional 1,100 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Baxter International by 23.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,519 shares of the medical instruments supplier’s stock valued at $96,000 after purchasing an additional 475 shares during the last quarter. Finally, Bruce G. Allen Investments LLC raised its stake in shares of Baxter International by 247.3% in the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 1,867 shares in the last quarter. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Stock Up 3.3 %

BAX opened at $36.61 on Friday. The firm’s 50-day simple moving average is $31.86 and its 200-day simple moving average is $34.06. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. Baxter International Inc. has a twelve month low of $28.33 and a twelve month high of $44.01. The firm has a market cap of $18.73 billion, a price-to-earnings ratio of -28.60, a PEG ratio of 0.93 and a beta of 0.60.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.67 billion. Equities research analysts anticipate that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be given a $0.17 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.86%. Baxter International’s dividend payout ratio is -53.13%.

Wall Street Analyst Weigh In

BAX has been the subject of a number of recent research reports. Barclays initiated coverage on shares of Baxter International in a research note on Thursday, February 20th. They issued an “overweight” rating and a $39.00 price objective for the company. Citigroup dropped their price objective on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. dropped their price objective on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Friday, February 21st. StockNews.com cut shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Monday, November 11th. Finally, Stifel Nicolaus dropped their price objective on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Baxter International presently has a consensus rating of “Hold” and a consensus target price of $38.33.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.